[Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor]

Acta Haematol Pol. 1991;22(1):92-9.
[Article in Polish]

Abstract

The appearance of antibodies to factor VIII is a serious complication in the treatment of haemophilia A. A protocol is presented aiming at suppression of the anticoagulant using continued treatment with factor VIII (25 u/kg b.w. twice weekly). Ten patients with previous maximal factor VIII antibody titre from 7 to 2900 Bethesda units were treated. So far the inhibitor was eradicated in 3 cases treated continuously for from 5 to 20 months. In two of these three cases successful surgical procedures were performed without anamnestic response.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Autoantibodies / immunology*
  • Autoimmune Diseases / blood
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy
  • Blood Transfusion*
  • Child
  • Factor VIII / administration & dosage*
  • Factor VIII / immunology*
  • Fibrinogen / administration & dosage*
  • Hemophilia A / blood
  • Hemophilia A / immunology*
  • Hemophilia A / therapy
  • Humans
  • Immune Tolerance / immunology
  • Male
  • Middle Aged

Substances

  • Autoantibodies
  • cryoprecipitate coagulum
  • Factor VIII
  • Fibrinogen